ArticleChina CDC weekly2025
Hypertension Control in China: Translation from Clinical Trial to Real-World Application - Preliminary Outcomes.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Practice and Effect Evaluation of Hypertension Homogenization Management Model Under the "Walking Hospital" Mode in Primary Medical Institutions.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the adaptability of the China Rural Hypertension Control Project (CRHCP) - a multifaceted village doctor-led intervention for blood pressure control in rural China - for widespread implementation in extension projects. This project comprises two phases: a pilot project and an extension project. It builds upon our CRHCP model, implementing a multi-level comprehensive hypertension management strategy targeting the general population across rural areas and township communities in China, aligning with national policies and local initiatives. In the pilot project, 5,088 hypertensive patients were enrolled. At baseline, 1,227 subjects (25.7%) met the 140/90 mmHg target for blood pressure control. After 13 months of intervention, the blood pressure control rate (<140/90 mmHg) reached 72.5%. In the extension project, 244,046 hypertensive patients were identified through screening of 1,002,845 residents in Changtu, Wujiang, and Tongguan. Average blood pressure decreased from 146.8/88.4 mmHg to 140.4/82.6 mmHg, and the proportion of patients with controlled blood pressure increased significantly from 20.8% to 44.0%. The translation of the CRHCP model into a public health program has demonstrated potential for enhancing hypertension control in selected regions of China. While these initial results are encouraging, further research and long-term evaluation are needed to confirm their effectiveness and adaptability. If proven successful, this model may offer a replicable framework for improving public health outcomes in other low- and middle-income countries and regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.